

6th January, 2024

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Update on the Definitive Agreement entered between Cipla Technologies LLC and Pulmatrix Inc. for development and commercialization of Pulmazole

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to the intimations dated 15th April, 2019, 13th July, 2020 and 9th November, 2021, we hereby notify that Cipla Technologies, LLC (“Cipla”), wholly owned step-down subsidiary of Cipla Limited and Pulmatrix Inc., have completed an amendment to the agreement for the development and commercialization of Pulmazole.

The parties have now agreed to:

- a. terminate the Phase 2b clinical trial for development of Pulmazole by 30th July, 2024.
- b. Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except United States of America.

This is for your information and records.

Thankyou

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode